March 3, 2026Open Access

Clinical outcome and tolerability of DS-8201 in patients with advanced HER2-positive breast cancer: a retrospective study

Key Points

DS-8201 demonstrated significantly better efficacy compared to treatment of physician's choice (TPC).
Patients with T-DM1-pretreated HER2-positive advanced breast cancer showed similar overall safety.
Observational analysis compared DS-8201 to TPC in HER2-positive patients with advanced disease.
Findings support the clinical use of DS-8201 as a promising therapeutic option for advanced breast cancer.

Abstract

DS-8201 showed significantly better efficacy and similar overall safety compared to TPC in patients with T-DM1-pretreated HER2-positive advanced breast cancer, supporting its use as a treatment option in this setting.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Wei Wu

Journals

American Journal of Translational Research

Actions

Institutions

Modern Cancer Hospital Guangzhou

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Clinical outcome and tolerability of DS-8201 in patients with advanced HER2-positive breast cancer: a retrospective study

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study